# Bioforce Nanosciences Holdings, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Bioforce Nanosciences Holdings, Inc.). ## Overview BioForce Nanosciences Holdings, Inc. is a U.S.-based microcap company that has shifted away from its original nanotechnology roots into nutritional supplements. Its current business centers on the BioForce Eclipse powder multivitamin and mineral supplement, which it private-labels through a Virginia manufacturer and distributes through retail and online channels. The company says it is trying to build brand awareness through social media, telemarketing, direct marketing, and B2B sales. It remains in an early commercial stage and has disclosed that it does not yet generate enough revenue to cover operating expenses. ## Products & services • BioForce Eclipse powder multivitamin and mineral supplement • Nutritional powders for active individuals • Vitamin and mineral beverage/supplement products • Private-label supplement manufacturing and distribution • Direct marketing and B2B sales of supplement products - **Nutritional supplements** (100%) — Powdered multivitamin and mineral supplements sold under the BioForce Eclipse brand. - **Private-label product sourcing** (0%) — Supplement products manufactured by third parties and sold under private-label arrangements. - BioForce Eclipse powder multivitamin and mineral supplement - Nutritional powders for active individuals - Vitamin and mineral beverage/supplement products - Private-label supplement manufacturing and distribution - Direct marketing and B2B sales of supplement products ## Customers BioForce targets retail and wholesale buyers that can place its supplement products into consumer channels, including retailers, sporting goods stores, supermarkets, mass merchandisers, grocery stores, retail pharmacies, and online marketplaces such as Amazon. It also seeks B2B relationships with distributors and vendor partners that can broaden shelf access and improve product placement. The company explicitly mentions health-conscious individuals and active consumers as the end users of its powders, vitamins, and beverages. It also identifies institutional outlets such as hospitals, medical clinics, universities, nursing homes, prisons, and other facilities as potential sales channels for its vitamin and mineral products. - **Retail channel partners** (primary) — Retailers, grocery stores, pharmacies, and mass merchandisers that buy supplement products for resale because they want branded wellness items with consumer demand. - **Online marketplaces** (primary) — E-commerce channels such as Amazon that buy or list the product to reach consumers directly and broaden geographic reach. - **B2B distributors** (primary) — Distributors and vendor partners that help place the product into multiple outlets and support the company's direct marketing strategy. - **Institutional and facility buyers** (secondary) — Hospitals, clinics, universities, nursing homes, prisons, and similar facilities that may purchase vitamin and mineral supplements for on-site use or resale. - **End consumers** (primary) — Health-conscious and active individuals who consume the Eclipse powder and related supplements for nutrition support. - Retailers that can stock BioForce Eclipse for consumer resale - Sporting goods and health food stores seeking active-lifestyle supplements - Supermarkets, grocery stores, and mass merchandisers - Online marketplaces such as Amazon for direct consumer reach - Distributors and B2B partners that can expand shelf access - Institutional buyers and facilities such as clinics, universities, and nursing homes - Health-conscious individuals and active consumers as end users ## Geography The company is headquartered in the United States and describes the U.S. as its core and intended expansion market. Management says it plans to expand marketing throughout the entire United States, which makes domestic distribution and brand-building the main geographic priorities. It currently sources private-label production from a manufacturer located in Virginia, so its supply chain is also U.S.-based. No country-level revenue disclosure was provided in the excerpts, and the business appears to be concentrated in the domestic market. - United States is the primary and intended expansion market - Management plans nationwide U.S. rollout rather than international expansion - Private-label manufacturing is currently located in Virginia - Sales and marketing are focused on U.S. retail and online channels - No country-level revenue split was disclosed in the excerpts ## Strategy BioForce's near-term strategy is to build a viable supplement business around BioForce Eclipse and related nutritional products after exiting its earlier nanotechnology business. Management is focused on brand awareness, direct marketing, telemarketing, social media, and B2B sales to secure retail placements and online demand. The company also wants to improve sourcing economics by evaluating alternative manufacturing arrangements if it can maintain quality. Because the business is undercapitalized and not yet self-funding, raising working capital is a central strategic requirement for survival and execution. - **Brand and demand generation** (short-term) — The company needs consumer awareness to create pull-through demand and convince retailers to carry the product. - **Channel expansion** (short-term) — Broader retail and online distribution is necessary to scale sales beyond a limited set of outlets. - **Supply chain and sourcing optimization** (medium-term) — The company wants to reduce product cost and improve economics while maintaining quality. - **Capital preservation and financing** (short-term) — The company has disclosed insufficient revenues and ongoing cash needs, making financing essential to continue operations. - Build brand awareness for BioForce Eclipse through targeted marketing - Expand direct marketing and B2B sales to win retail placements - Use social media and telemarketing to generate consumer demand - Broaden distribution across U.S. retail and online channels - Evaluate lower-cost sourcing options without sacrificing product quality - Raise working capital to fund operations and avoid business disruption ## Risks The most immediate risk is going concern and liquidity risk, because management states that the company does not have sufficient revenues to pay operating expenses and may need to cease operations or substantially change its business plan if it cannot raise capital. Commercial execution risk is also high because the company is still building brand awareness and has not yet established stable demand or broad distribution for its supplement products. Supply-chain and counterparty risk matter because the company relies on a third-party manufacturer and a private-label arrangement, which can affect cost, availability, and control over the product formula. More broadly, the supplement industry faces regulatory, quality, and consumer-preference risks, and the company is exposed to competition from larger brands with stronger distribution and marketing budgets. - **Going concern and liquidity shortfall** [critical] — Management states that the company does not have sufficient revenues to cover operating expenses and needs additional capital to continue operations. - **Dependence on external financing and related parties** [high] — Recent cash inflows came from related parties and capital contributions, indicating the business depends on non-operating funding. - **Commercial adoption risk** [high] — The company is still trying to establish brand awareness and reported no orders in one disclosed quarter, showing uncertain demand. - **Third-party manufacturing and private-label dependence** [medium] — The product is manufactured by an outside supplier and the distributor owns the formula rights, limiting control over supply and economics. - **Supplement regulation and product quality** [medium] — Dietary supplements are subject to FDA rules and quality expectations, which can affect market access and liability. - Going concern risk due to insufficient revenue and ongoing cash burn - Dependence on related-party or external financing to fund operations - Limited market traction and uncertain consumer demand for BioForce Eclipse - Reliance on third-party manufacturing and private-label supply arrangements - Regulatory and quality-compliance risk for dietary supplements - Competitive pressure from established supplement brands and retailers - Execution risk in building retail and online distribution from a small base ## Accounting Revenue recognition is a key accounting issue because the company sells physical supplement products and recognizes revenue when control transfers under ASC 606, which can be affected by consignment terms, distributor arrangements, and the timing of shipment or sale. The company also highlights impairment of long-lived assets as a critical policy, which matters because any underperforming assets from its prior business or current operations may need write-downs. Quarterly results can be volatile because the company is small, has limited revenue, and relies on related-party funding and working-capital support, so small changes in orders or expenses can materially affect reported results. Investors should also watch accruals for board and officer compensation and accounts payable, since these estimates can meaningfully shape short-term cash flow and net loss presentation. - **Revenue recognition under ASC 606** — Can shift reported sales between periods - **Impairment of long-lived assets** — Can create material non-cash charges - **Accrued compensation and payables** — Affects liabilities, expenses, and cash flow - **Going concern disclosures** — Important for valuation and financial statement interpretation - Revenue recognition under ASC 606 affects when supplement sales are recorded - Consignment and distributor terms can delay revenue until sale to end customers - Impairment of long-lived assets may create non-cash write-downs - Small revenue base makes quarterly results highly volatile and hard to compare - Accrued board and officer compensation can materially affect liabilities and losses - Related-party funding influences cash flow presentation and going-concern assessment --- *Last updated: 2026-08-11T04:46:22.644263+00:00*